ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)

被引：1
|
作者：
Johnson, Peter W. M. [1 ]
Caddy, Joshua [2 ]
Cumin, Tom [1 ]
Merton, Bridgen [1 ]
Maishman, Tom [2 ]
Galanopoulou, Angelic [2 ]
Griffiths, Gareth [2 ]
Davies, Andrew [1 ]
机构：
[1] CRUK Ctr, Southampton, Hants, England
[2] Southampton Clin Trials Unit, Southampton, Hants, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT162
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinicopathologic Significance of CD11c, CD16 and FOXP3 Expression in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Rituximab, Cyclophosphamide, Anthracycline, Vincristine, and Prednisolone (R-CHOP) Combination Chemotherapy
    Oh, Sung Yong
    Jung, Jin Sook
    Kim, Sung Hyun
    BLOOD, 2012, 120 (21)
  • [22] Liposomal doxorubicin in combination with vincristine, cyclophosphamide and prednisone in patients with aggressive diffuse large B-cell lymphomas (DLBCL)
    Stulginskaya, Marina A.
    Dudnichenko, Alexander S.
    ANNALS OF ONCOLOGY, 2004, 15 : 155 - 156
  • [23] Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma
    Roschewski, Mark
    Dunleavy, Kieron
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2428 - 2437
  • [24] Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study
    Morschhauser, Franck
    Feugier, Pierre
    Flinn, Ian W.
    Gasiorowski, Robin E.
    Greil, Richard
    Illes, Arpad
    Johnson, Nathalie A.
    Larouche, Jean-Francois
    Lugtenburg, Pieternella J.
    Patti, Caterina
    Salles, Gilles
    Trneny, Marek
    de Vos, Sven
    Mir, Farheen
    Kornacker, Martin
    Punnoose, Elizabeth A.
    Samineni, Divya
    Szafer-Glusman, Edith
    Petrich, Adam
    Sinha, Arijit
    Mobasher, Mehrdad
    Zelenetz, Andrew D.
    BLOOD, 2018, 132
  • [25] Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)
    Younes, Anas
    Flinn, Ian
    Berdeja, Jesus G.
    Friedberg, Jonathan W.
    Alberti, Sara
    Thieblemont, Catherine
    Morschhauser, Franck
    Hellemans, Peter
    Hall, Brett
    Smit, Johan
    Skee, Donna
    de Vries, Ronald
    Todorovic, Marija
    Khan, Imran
    Fourneau, Nele
    Oki, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515
    Stopeck, Alison T.
    Unger, Joseph M.
    Rimsza, Lisa M.
    Farnsworth, Brent
    LeBlanc, Michael
    Iannone, Maria
    Fisher, Richard I.
    Miller, Thomas P.
    BLOOD, 2010, 116 (21) : 260 - 261
  • [27] A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)
    Younes, Anas
    Zinzani, Pier Luigi
    Sehn, Laurie Helen
    Johnson, Peter W. M.
    Gascoyne, Randy D.
    Ahmedi, Tahamtan
    Bellew, Kevin M.
    Verrneulen, Jessica
    Zhuang, Sen Hong
    Sun, Stevan
    Staudt, Louis M.
    Wilson, Wyndham Hopkins
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Diffuse large B-cell lymphoma: R-CHOP forever?
    Jedrzejczak, Wieslaw W.
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2015, 125 (10): : 713 - 714
  • [29] PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RITUXIMAB PLUS CHOP (R-CHOP)
    Go, S. I.
    Park, M. J.
    Kim, H. G.
    Kang, M. H.
    Lee, G. W.
    HAEMATOLOGICA, 2016, 101 : 686 - 687
  • [30] Prognostic significance of primary extranodal diffuse large B-cell lymphoma (DLBCL) in patients treated with R-CHOP
    Hui, D.
    Proctor, B.
    Donaldson, J.
    Shenkier, T.
    Hoskins, P.
    Klasa, R.
    Savage, K.
    Gascoyne, R.
    Connors, J. M.
    Sehn, L. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 186 - 187
12345